Quarterly ResultMay 4, 2026, 07:12 AM
Axsome Q1 Revenue $191.2M, +57% YoY; AUVELITY Approved for AD Agitation
AI Summary
Axsome Therapeutics reported strong Q1 2026 financial results with total net product revenue of $191.2 million, a 57% year-over-year increase. AUVELITY sales grew 59% to $153.2 million, and SUNOSI sales increased 34% to $33.9 million. The FDA approved AUVELITY for agitation associated with dementia due to Alzheimer’s disease, with a commercial launch planned for June 2026. The company also submitted an NDA for AXS-12 for narcolepsy and added AXS-20 for schizophrenia and Tourette syndrome to its pipeline, despite reporting a net loss of $64.5 million.
Key Highlights
- Total net product revenue for Q1 2026 was $191.2 million, a 57% year-over-year increase.
- AUVELITY net product sales reached $153.2 million in Q1 2026, growing 59% year-over-year.
- SUNOSI net product revenue was $33.9 million, representing 34% year-over-year growth.
- SYMBRAVO net product sales were $4.1 million for the first quarter of 2026.
- AUVELITY was approved by the FDA for the treatment of agitation associated with dementia due to Alzheimer’s disease.
- An NDA for AXS-12 for the treatment of cataplexy in narcolepsy was submitted to the FDA.
- Net loss for Q1 2026 was $64.5 million, or $(1.26) per share.
- Cash and cash equivalents totaled $305.1 million as of March 31, 2026.